425: Bellevue Life Sciences Acquisition Corp. Amends Business Combination Agreement with OSR Holdings Co., Ltd.

Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. have amended their business combination agreement, adjusting the aggregate consideration and removing references to a previous acquisition target.

Summary

• Bellevue Life Sciences Acquisition Corp. (BLAC) and OSR Holdings Co., Ltd. have entered into an Amended and Restated Business Combination Agreement (A&R BCA) on May 23, 2024.
• The A&R BCA modifies the original agreement dated November 16, 2023, primarily to remove references to the proposed acquisition of Landmark BioVentures AG by OSR Holdings.
• The aggregate consideration has been reduced from 25,033,961 shares of BLAC Common Stock to 24,461,214 shares.
• The Aggregate Consideration Value has been reduced from $250,339,610 to $244,612,136.
• Changes were made to the designation of the post-closing Board of Directors of BLAC.
• Steven Reed resigned from the BLAC Board of Directors effective May 24, 2024.
• Phil Geon Lee was appointed as a new director to the BLAC Board effective May 27, 2024.
• BLAC will prepare a proxy statement/prospectus to be filed with the SEC and mailed to BLAC’s stockholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are adjustments to the deal terms, the business combination is still progressing. The appointment of a new director is a positive sign, but the reduced consideration and removal of the Landmark BioVentures AG acquisition temper the overall outlook.

Positives

• The business combination is still proceeding, indicating continued confidence in OSR Holdings.
• The BLAC Board formed a separate committee (the M&A Committee), consisting of independent directors, to review and consider these interests during the negotiation of the Business Combination Agreement, the A&R BCA, and in evaluating and unanimously approving, as members of the BLAC Board, the Business Combination Agreement and the A&R BCA.
• Phil Geon Lee's appointment brings extensive experience in legal and investment sectors to the BLAC Board.

Negatives

• The reduction in aggregate consideration and value may indicate a revised valuation of OSR Holdings.
• The removal of the Landmark BioVentures AG acquisition suggests a change in OSR Holdings' strategic direction.
• Steven Reed's resignation creates vacancies in key committees, although these have been filled.

Risks

• The satisfaction of closing conditions to the proposed business combination remains a risk.
• The outcome of any legal proceedings related to the business combination could impact the deal.
• Failure to obtain approval from BLAC stockholders could prevent the completion of the business combination.
• The COVID-19 pandemic or other global health disruptions could affect the parties' ability to consummate the business combination.
• The inability to obtain or maintain the listing of the surviving company's common stock on Nasdaq is a risk.
• Changes in applicable laws or regulations could adversely affect the business combination.

Future Outlook

The document includes forward-looking statements regarding the satisfaction of closing conditions, the timing of completion, and the future performance of the company, all of which are subject to risks and uncertainties.

Management Comments

• The Board of Directors of the Company has unanimously determined that the Business Combination is fair to, and in the best interests of, the Company and its stockholders.
• The BLAC Board has approved and adopted this Agreement and declared its advisability and approved the payment of the Per Share Consideration to the Participating Company Stockholders at Closing pursuant to this Agreement and the other transactions contemplated by this Agreement.

Industry Context

The announcement reflects ongoing activity in the SPAC market, where companies seek to merge with existing businesses to gain public listing. The amendment suggests a dynamic deal-making environment where terms and targets can change.

Comparison to Industry Standards

• SPAC mergers often involve adjustments to deal terms based on due diligence and market conditions.
• Comparable SPAC transactions may have similar structures involving stock consideration and earn-out provisions.
• The valuation metrics, such as the Aggregate Consideration Value, would typically be compared to industry multiples for similar biotechnology companies.

Management Changes

Stakeholder Impact

• Shareholders of BLAC will be asked to vote on the amended business combination.
• The completion of the business combination will impact the future direction and performance of the combined company.
• Employees of OSR Holdings will be integrated into the combined company.

Next Steps

• BLAC will prepare and file a proxy statement/prospectus with the SEC.
• BLAC will mail the proxy statement/prospectus to its stockholders.
• BLAC will hold a stockholders meeting to vote on the business combination and related proposals.
• The parties will work to satisfy the remaining closing conditions and consummate the business combination.

Key Dates